Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

T cell immunity to COVID-19 vaccines
E. John Wherry, Dan H. Barouch
Science (2022) Vol. 377, Iss. 6608, pp. 821-822
Open Access | Times Cited: 175

Showing 26-50 of 175 citing articles:

Development of an engineered extracellular vesicles-based vaccine platform for combined delivery of mRNA and protein to induce functional immunity
Xin Luo, Kathleen M. McAndrews, Kent A. Arian, et al.
Journal of Controlled Release (2024) Vol. 374, pp. 550-562
Open Access | Times Cited: 5
Structural and functional properties of the SARS-CoV-2 spike protein: Potential vaccine and drug development for COVID-19
Reed L. Berkowitz, David A. Ostrov
Elsevier eBooks (2025), pp. 57-74
Closed Access
Low agreement and frequent invalid controls in two SARS-CoV-2 T-cell assays in people with compromised immune function
Annette Audigé, Alain Amstutz, Macé M. Schuurmans, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0317965-e0317965
Open Access
Immunologic and inflammatory consequences of SARS-CoV-2 infection and its implications in renal disease
Hiam Naiditch, Michael R. Betts, H. Benjamin Larman, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access
Combined immunization with SARS-CoV-2 spike and SARS-CoV nucleocapsid protects K18-hACE2 mice but increases lung pathology
Jae‐Kwan Kim, A. V. Kachko, Prabhuanand Selvaraj, et al.
npj Vaccines (2025) Vol. 10, Iss. 1
Open Access
Novel Vaccines Targeting the Highly Conserved SARS-CoV-2 ORF3a Ectodomain Elicit Immunogenicity in Mouse Models
Jacob Meza, Elizabeth M. Glass, Avinaash K. Sandhu, et al.
Vaccines (2025) Vol. 13, Iss. 3, pp. 220-220
Open Access
Estimating long-term vaccine effectiveness against SARS-CoV-2 variants: a model-based approach
Alexandra B. Hogan, Patrick Doohan, Sean L. Wu, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 13
Differential requirement of neutralizing antibodies and T cells on protective immunity to SARS-CoV-2 variants of concern
Patrick O. Azevedo, Natália Satchiko Hojo-Souza, Lídia Faustino, et al.
npj Vaccines (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 12
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger, Larry A. Saltzman, Lore Gruenbaum, et al.
Blood Cancer Discovery (2022) Vol. 3, Iss. 6, pp. 481-489
Open Access | Times Cited: 21
mRNA, the beginning of a new influenza vaccine game
Simone Pecetta, Rino Rappuoli
Proceedings of the National Academy of Sciences (2022) Vol. 119, Iss. 50
Open Access | Times Cited: 19
Effectiveness of BNT162b2 and CoronaVac vaccines in preventing SARS-CoV-2 Omicron infections, hospitalizations, and severe complications in the pediatric population in Hong Kong: a case-control study
Vincent Ka Chun Yan, Franco Wing Tak Cheng, Celine Sze Ling Chui, et al.
Emerging Microbes & Infections (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Controllable self-replicating RNA vaccine delivered intradermally elicits predominantly cellular immunity
Tomokazu Amano, Hong Yu, Misa Amano, et al.
iScience (2023) Vol. 26, Iss. 4, pp. 106335-106335
Open Access | Times Cited: 11
Immune responses of different COVID-19 vaccination strategies by analyzing single-cell RNA sequencing data from multiple tissues using machine learning methods
Hao Li, Qinglan Ma, Jingxin Ren, et al.
Frontiers in Genetics (2023) Vol. 14
Open Access | Times Cited: 11
One-year antibody durability induced by EuCorVac-19, a liposome-displayed COVID-19 receptor binding domain subunit vaccine, in healthy Korean subjects
Jonathan F. Lovell, Kazutoyo Miura, Yeong Ok Baik, et al.
International Journal of Infectious Diseases (2023) Vol. 138, pp. 73-80
Open Access | Times Cited: 11
mRNAs encoding self-DNA reactive cGAS enhance the immunogenicity of lipid nanoparticle vaccines
Dania Zhivaki, Emily A. Gosselin, Debrup Sengupta, et al.
mBio (2023) Vol. 14, Iss. 6
Open Access | Times Cited: 11
Vaccine development against tuberculosis before and after Covid-19
Stefan H. E. Kaufmann
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Omicron BA.4/5 Neutralization and T-Cell Responses in Organ Transplant Recipients After Booster Messenger RNA Vaccine: A Multicenter Cohort Study
Victor H. Ferreira, Matthew Ierullo, Faranak Mavandadnejad, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 2, pp. 229-236
Open Access | Times Cited: 10
Heterologous versus homologous boosting elicits qualitatively distinct, BA.5–cross-reactive T cells in transplant recipients
Elizabeth A. Thompson, Wabathi Ngecu, Laila Stoddart, et al.
JCI Insight (2023) Vol. 8, Iss. 10
Open Access | Times Cited: 10
Prolonged SARS-CoV-2 T Cell Responses in a Vaccinated COVID-19-Naive Population
Vassiliki Pitiriga, Myrto Papamentzelopoulou, Kanella E. Konstantinakou, et al.
Vaccines (2024) Vol. 12, Iss. 3, pp. 270-270
Open Access | Times Cited: 3
Unlocking cancer vaccine potential: What are the key factors?
Michael Grant, Lian Ni Lee, Senthil Chinnakannan, et al.
Human Vaccines & Immunotherapeutics (2024) Vol. 20, Iss. 1
Open Access | Times Cited: 3
Factors associated with immune responses to SARS-CoV-2 vaccination in autoimmune disease individuals
Erik Anderson, Michael D. Powell, Emily Yang, et al.
JCI Insight (2024) Vol. 9, Iss. 13
Open Access | Times Cited: 3
Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates
Matthew Gagné, Barbara J. Flynn, Shayne F. Andrew, et al.
Nature Immunology (2024) Vol. 25, Iss. 10, pp. 1913-1927
Open Access | Times Cited: 3
Adenoviral-vectored next-generation respiratory mucosal vaccines against COVID-19
Sam Afkhami, Alisha Kang, Vidthiya Jeyanathan, et al.
Current Opinion in Virology (2023) Vol. 61, pp. 101334-101334
Open Access | Times Cited: 9
Chemical and biological conjugation strategies for the development of multivalent protein vaccine nanoparticles
Jaeyoung Park, Thomas Pho, Julie A. Champion
Biopolymers (2023) Vol. 114, Iss. 8
Closed Access | Times Cited: 9
Safety, immunogenicity, and efficacy of a modified COVID-19 mRNA vaccine, SW-BIC-213, in healthy people aged 18 years and above: a phase 3 double-blinded, randomized, parallel controlled clinical trial in Lao PDR (Laos)
Yi Fang, Jingxin Li, Davone Duangdany, et al.
EClinicalMedicine (2023) Vol. 67, pp. 102372-102372
Open Access | Times Cited: 9

Scroll to top